Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimal Anticoagulation Strategy In Stroke Related to CANCER (OASIS-CANCER Study)

NCT02743052 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT02743052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02743052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimal Anticoagulation Strategy In Stroke Related to CANCER (OASIS-CANCER Study)
Lead sponsor
Samsung Medical Center
Phase
Observational
Overall status
Unknown status
Start date
October 31, 2009
Completion date
December 31, 2018
Enrollment
400 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, stroke